Clover Health Investments has seen its stock price move sharply in recent years, which puts fresh focus on whether today's valuation lines up with the revenue the business is generating. For anyone following Clover Health, the live question is how that share price ties back to its sales base rather than just to headlines and momentum.
-
Over the past 3 years the stock has returned about 365.0%, which puts real weight on the issue of how much sales investors are effectively paying for at the current market value.
-
Recent recognition of Clover Health's Medicare Advantage PPO plans with a 5 Star rating for 2027 and ongoing focus on preventive care may support expectations around future member volumes and revenue durability, which matters directly for how its sales are being valued today.
-
Your read on Clover Health Investments is one view; the desks covering it have another. See what analysts think Clover Health Investments's shares could be worth .
The issue now is whether the recent share price level for Clover Health is justified by its sales when viewed through this single valuation lens.
If you want a wider watchlist of companies where investors are also weighing price against business fundamentals, a focused screener of 28 high quality undervalued stocks is a useful next step.
Where Does Clover Health Investments Sit on Sales?
P/S is a useful lens for Clover Health Investments because investors are focused on how much they are paying for each dollar of revenue rather than current earnings. On this measure, the stock trades on a P/S of 1.0x, close to both the tailored fair multiple implied by its fundamentals and the 1.3x average across the wider Healthcare group. Compared with a peer average of about 2.0x, the revenue multiple screens as lower than many similar companies in the sector.
Because the fair benchmark adjusts for Clover Health Investments' growth profile, margins, scale and risks, the current P/S sitting near that level points to a valuation that is broadly about right on this framework. Because the 5 Star Medicare Advantage PPO rating for 2027 improves product credibility and could influence how investors view future revenue quality, that recognition may help explain why the P/S has converged toward the modelled fair range rather than trading at a steeper discount or premium. Explore the numbers behind Clover Health Investments's P/S valuation .
The Clover Health Investments Narrative: What Would Justify Today's Price?
Narratives for Clover Health Investments pick up where the P/S puzzle leaves off, by spelling out the specific revenue growth paths, margin shapes and earnings outcomes that would need to play out for the current share price to look materially higher or lower from here. Instead of only giving one valuation figure, they lay out the future that figure relies on so you can see what to watch on Simply Wall St's Community page and judge whether those assumptions still line up with reality.
One of the top community narratives on Clover Health Investments: 11% undervalued
"The Clover Assistant software platform and the non delegated risk model are viewed as key potential earnings drivers, which bullish analysts see as important…"
Discover why this Narrative puts Clover Health Investments at 11% undervalued .
The key piece Clover Health investors have not checked yet
Valuation only shows what the market is willing to pay today, while the projections professional analysts publish sketch out a very different picture of where they think Clover Health Investments could be a few years from now. Explore where analysts expect Clover Health Investments to be in a few years .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CLOV .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
